Researchers are continuing to explore how hemp-derived cannabinoids may interact with the immune system, especially in inflammatory conditions such as rheumatoid arthritis (RA). In the study “Cannabigerol (CBG) Modulates Neutrophil Activity and Ameliorates Rheumatoid Arthritis Pathogenesis,” scientists investigated how purified CBG affected neutrophils, a type of immune cell heavily involved in inflammation and joint damage associated with RA. The findings demonstrated that CBG helped reduce inflammatory signaling and immune-cell migration in both laboratory and animal models. (University of Haifa)

The research showed that CBG significantly reduced the release of pro-inflammatory cytokines such as IL-6 and TNF-α, which are commonly associated with autoimmune inflammation. Researchers also observed that CBG influenced several important inflammatory pathways connected to immune activation and neutrophil response. In animal models of rheumatoid arthritis, CBG treatment improved arthritis severity scores while reducing immune-cell recruitment into inflamed joints. (University of Haifa)

These findings continue supporting growing scientific interest in CBG as a unique minor cannabinoid with potential anti-inflammatory and immune-supporting properties. While the research remains preclinical and additional human studies are still needed, studies like this help expand understanding of how cannabinoids may interact with the body’s endocannabinoid and immune systems to support overall wellness and balance.

Source

Aswad M, Pechkovsky A, Hamza H, Louria-Hayon I. Cannabigerol (CBG) Modulates Neutrophil Activity and Ameliorates Rheumatoid Arthritis Pathogenesis. Pharmaceuticals. Published April 2026. (University of Haifa) https://pubmed.ncbi.nlm.nih.gov/42075816/